Catarina Gregório, João R Agostinho, Daniel Caldeira, Marta Vilela, Ana Abrantes, Margarida Batista, Filipa Abrantes, Ana Beatriz Garcia, Catarina Campos, Isabel Conceição, Fausto J Pinto, Dulce Brito
{"title":"Clinical characteristics and outcomes of Tafamidis-treated ATTR-CM patients in a real-world cohort: Comparison with the results of pivotal trials.","authors":"Catarina Gregório, João R Agostinho, Daniel Caldeira, Marta Vilela, Ana Abrantes, Margarida Batista, Filipa Abrantes, Ana Beatriz Garcia, Catarina Campos, Isabel Conceição, Fausto J Pinto, Dulce Brito","doi":"10.1016/j.repc.2026.04.011","DOIUrl":"https://doi.org/10.1016/j.repc.2026.04.011","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease that leads to heart failure and increased mortality. Pivotal clinical trials - ATTR-ACT, ATTRibute-CM and HELIOS-B - have provided robust evidence supporting the efficacy of TTR stabilizers (Tafamidis and Acoramidis) and the TTR-synthesis inhibitor Vutrisiran in reducing mortality and cardiovascular events. This study aims to compare the clinical characteristics and cardiovascular outcomes of a real-world Portuguese cohort of patients with ATTR-CM treated with tafamidis to those reported in pivotal clinical trials.</p><p><strong>Methods: </strong>Single-center, observational study including consecutive patients with ATTR-CM treated with tafamidis 61 mg once a day. Clinical, laboratory, and echocardiographic data were collected and compared with published results from the ATTR-ACT, ATTRibute-CM, and HELIOS-B trials. The primary endpoint was all-cause mortality at 24 months, assessed by Kaplan-Meier survival analysis. Secondary outcomes included cardiovascular-related hospitalizations and quality of life, assessed by KCCQ-OS during follow-up, both of which were compared across studies.</p><p><strong>Results: </strong>A total of 89 patients were included (76 males; 39 with hereditary ATTR-CM and 50 with wild-type ATTR-CM). The Portuguese real-world cohort was older than the ATTR-ACT and HELIOS-B study populations (mean age 78.6 vs. 74.5 vs. 77.0 years, respectively; p<0.001) and exhibited better functional capacity as assessed by New York Heart Association class compared to ATTR-ACT, ATTRibute-CM and HELIOS-B (New York Heart Association (NYHA) I: 30 vs. 9 vs. 12 vs. 15%, respectively; p<0.001). Echocardiography showed higher LVEF (55 vs. 48%, p<0.001) and better GLS (-15 vs -9%, p<0.001) compared with ATTR-ACT. NT-proBNP levels were comparable across cohorts (2639 vs. 2996 vs. 2946 vs. 2021 pg/mL, respectively; p>0.05). Hereditary ATTR was significantly more prevalent in the Portuguese cohort (44%) compared to ATTR-ACT (24%), ATTRibute-CM (10%), and HELIOS-B (11%; p<0.001), reflecting the endemic p.Val50Met mutation in Portugal. Over a follow-up of 27.4 ± 19.3 months, seven patients (7.9%) experienced heart failure hospitalizations and five patients (5.4%) died, including three cardiovascular deaths, corresponding to an annualized cardiovascular-related hospitalization rate of 0.034 events per patient-year. The 24-month all-cause mortality of 5.6% was considerably lower than reported in ATTR-ACT (24.2%), ATTRibute-CM (15.9%), and HELIOS-B (11.4%). However, KCCQ-OS scores were lower than in ATTRibute-CM and HELIOS-B (both p<0.001), likely reflecting comorbidities, and neurological involvement in hereditary cases.</p><p><strong>Conclusions: </strong>Patients receiving tafamidis 61 mg for ATTR-CM in this real-world cohort were older, had a higher prevalence of hereditary ATTR, and demonstrated better baseline fun","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Obesity and the heart: \"Dangerous Liaisons\".","authors":"Anabela Raimundo, Fausto J Pinto","doi":"10.1016/j.repc.2026.08.008","DOIUrl":"https://doi.org/10.1016/j.repc.2026.08.008","url":null,"abstract":"<p><p>Obesity is the epidemic of the 21st century, with a high impact on global health, and on cardiovascular health in particular, being simultaneously an independent cardiovascular risk factor and being in the etiopathogenesis of other risk factors, namely diabetes. The development of new drugs with proven efficacy in its treatment, such as GLP1 agonists, and dual GLP1 and GIP agonists, with a significant impact on cardiovascular, renal, and other diseases, constitutes a true revolution in the treatment of patients with obesity and cardiovascular disease (CVD). The emergence of the new concept of cardio-renal-metabolic syndrome, in which the presence of excess and/or dysfunctional adipose tissue translates into a set of pathophysiological mechanisms that lead to the development of cardiac, renal, and metabolic diseases, is relatively recent. However, it reflects an increasingly present reality in obese patients, where the coexistence of these pathologies represents a significant worsening of the prognosis and greater difficulty in their management. Given the challenges in prevention, diagnosis, and treatment that patients with adiposopathy and CVD represent, it is clearly beneficial that their approach be carried out by multidisciplinary teams in order to effectively respond to the multiple challenges that this pathology currently presents.</p>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Margarida G Figueiredo, Leonor Magalhães, Bruno Valente, Hélder Santos, Pedro Silva Cunha, Sofia Jacinto, Guilherme Portugal, Ana Lousinha, Pedro Coelho, Rui Cruz Ferreira, Mário Martins Oliveira
{"title":"Transvenous Lead Extraction Using the PISA Approach: A Decade of Experience from a National Referral Centre.","authors":"Margarida G Figueiredo, Leonor Magalhães, Bruno Valente, Hélder Santos, Pedro Silva Cunha, Sofia Jacinto, Guilherme Portugal, Ana Lousinha, Pedro Coelho, Rui Cruz Ferreira, Mário Martins Oliveira","doi":"10.1016/j.repc.2026.04.010","DOIUrl":"https://doi.org/10.1016/j.repc.2026.04.010","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The widespread implantation of cardiovascular implantable electronic devices (CIEDs) has led to a growing demand for safe and effective transvenous lead extraction (TLE), particularly concerning device-related infection, venous occlusions and lead dysfunction. As procedural complexity increases, so does the importance of adopting reliable and adaptable extraction strategies. We present a comprehensive, single referral centre experience using the PISA technique - a rotational sheath-based approach - to perform transvenous lead extraction over a 10-year period.</p><p><strong>Methods: </strong>This retrospective study included all patients undergoing TLE at a national referral centre between February 2013 and December 2024. Extractions were initially performed using simple traction as the first-line approach, and in all cases where simple traction was unsuccessful, the PISA approach for lead extraction was employed. Clinical and radiological success, complications, and mortality were analyzed.</p><p><strong>Results: </strong>A total of 283 patients underwent extraction of 530 leads, with a median lead dwell time of 96 months (IQR: 48-144). The majority of devices were pacemakers (62.9%), followed by cardiac resynchronisation devices (20.2%) and transvenous implanted cardioverter defibrillators (15.9%). Infection was the predominant indication (74.6%). The majority of procedures were performed via a superior approach. Clinical success was achieved in 97.5% of cases, whereas complete radiological success was achieved in 92.9% of patients. Major complications were observed in 2.8% of the procedures. In-hospital mortality rate was 3.9%, with only one death (0.4%) related to a major complication (not intra-procedure). During a median follow-up of 39 months (IQR: 17-74), all-cause mortality was 22.3%. Of these deaths, 3.9% occurred during the index hospitalization for TLE, 6.4% within the first year post-procedure, and 12.0% beyond the first year. Rehospitalisations due to cardiovascular or non-cardiovascular causes were observed in 19.8% of patients throughout the follow-up period.</p><p><strong>Conclusion: </strong>TLE extraction with the PISA technique is a high effective methodology, with favourable complication and mortality rates in patients with CIED. The implementation of structured peri-procedural protocols and a growing team experience may contribute to support a high-successfully programme.</p>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joana Certo Pereira, Pedro Galvão Santos, Diogo Cavaco, Pedro Adragão
{"title":"The ICD trilogy: From transvenous to subcutaneous to extravascular.","authors":"Joana Certo Pereira, Pedro Galvão Santos, Diogo Cavaco, Pedro Adragão","doi":"10.1016/j.repc.2026.05.010","DOIUrl":"https://doi.org/10.1016/j.repc.2026.05.010","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149326605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on \"Costs and consequences of cardiovascular toxicity due to Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia\".","authors":"Swarupanjali Padhi, Prashant Ramdas Kokiwar, Janvi Patel","doi":"10.1016/j.repc.2026.06.009","DOIUrl":"https://doi.org/10.1016/j.repc.2026.06.009","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149326604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Iñigo Anduaga, Teresa Espinosa, Alejandro Alcaraz, Laura Sanchis, Carlos Igor Morr-Verenzuela, Blanca Domenech-Ximenos, Pedro Cepas-Guillén, Marta Sitges, Xavier Freixa, Eduardo Flores-Umanzor
{"title":"Percutaneous management of paradoxical embolism due to coexisting patent foramen ovale and pulmonary arteriovenous malformation: A case report","authors":"Iñigo Anduaga, Teresa Espinosa, Alejandro Alcaraz, Laura Sanchis, Carlos Igor Morr-Verenzuela, Blanca Domenech-Ximenos, Pedro Cepas-Guillén, Marta Sitges, Xavier Freixa, Eduardo Flores-Umanzor","doi":"10.1016/j.repc.2026.04.008","DOIUrl":"10.1016/j.repc.2026.04.008","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 11","pages":"Pages 661-662"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cristina Gavina, Daniel Seabra Carvalho, Marta Afonso Silva, Ana Sofia Freitas, Nuno Lourenço-Silva, Mariana Canelas-Pais, Cristina Jácome, Francisco Araújo
{"title":"Low-density lipoprotein cholesterol reduction and its effect on all-cause death: A sub-analysis of the population-based cohort study LATINO","authors":"Cristina Gavina, Daniel Seabra Carvalho, Marta Afonso Silva, Ana Sofia Freitas, Nuno Lourenço-Silva, Mariana Canelas-Pais, Cristina Jácome, Francisco Araújo","doi":"10.1016/j.repc.2026.04.009","DOIUrl":"10.1016/j.repc.2026.04.009","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Reducing LDL-C is effective in reducing the risk of cardiovascular events, but its effect on all-cause mortality in real-world practice has yet to be estimated. We used a real-world evidence approach to analyze the impact of reducing LDL-C on all-cause mortality.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using electronic health records from individuals aged 40–85 years in Matosinhos, Portugal, from 1/1/2000 to 31/12/2020. Patients with ≥2 LDL-C results one year apart were categorized into four LDL-C reduction cohorts ([0–10%[, [10–30%[, [30–50%[, ≥50%). The primary outcome was all-cause death at one, three, and five years in LDL-C reduction cohorts (0–10% as reference).</div></div><div><h3>Results</h3><div>A total of 83<!--> <!-->727 individuals were included: 19<!--> <!-->177 in the [0–10%[LDL-C reduction cohort; 30<!--> <!-->774 in the [10–30%[, 22<!--> <!-->601 in the [30–50%[, and 11<!--> <!-->175 in the ≥50%. At 1 year, those with ≥50% LDL-C reduction achieved a 42% decrease in the risk of death (HR 0.58, 95%CI 0.43–0.79) and those with [10–30%[or [30–50%[LDL-C reductions a 25% decrease (HR 0.75, 95%CI 0.59–0.97; HR 0.75, 95%CI 0.58–0.97, respectively). The protective effects of LDL-C reduction became more evident over time (HRs 0.52–0.65). Patients with LDL-C levels ≥150 mg/dL benefited the most from more aggressive LDL-C reduction in the three follow-up periods (HRs 0.31–0.64).</div></div><div><h3>Conclusions</h3><div>Higher reductions in LDL-C are associated with lower risk of all-cause mortality, especially in individuals with higher LDL-C levels. These findings underscore the relevance of LDL-C as a modifiable risk factor and the need for aggressive LDL-C reduction strategies.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 11","pages":"Pages 635-644"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gonçalo Ferraz-Costa, Ana Luísa Silva, Ana Rita Ramalho, Lino Gonçalves, Paulo Donato, Rogério Teixeira
{"title":"Feasibility and safety of oral propranolol for heart rate control in pre-TAVI cardiac CT in severe aortic stenosis: A prospective study","authors":"Gonçalo Ferraz-Costa, Ana Luísa Silva, Ana Rita Ramalho, Lino Gonçalves, Paulo Donato, Rogério Teixeira","doi":"10.1016/j.repc.2026.05.008","DOIUrl":"10.1016/j.repc.2026.05.008","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Heart rate (HR) control may improve cardiac computed tomography angiography (CCTA) image quality in preprocedural planning for transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis (AS). Beta-blockers, though useful for HR reduction, pose hemodynamic risks in AS patients. Propranolol, a non-selective beta blocker, may offer a safe and effective solution, but its role in this context remains uncertain. The aim of this paper is to assess the feasibility and safety of oral propranolol for HR control in severe AS patients undergoing pre-TAVI CCTA.</div></div><div><h3>Methods</h3><div>This prospective, single-center study involved 113 severe AS patients scheduled for pre-TAVI CCTA. Oral propranolol was administered according to baseline HR and individualized clinical assessment: patients with HR 55–64 bpm were eligible for 5 mg, while those with HR >65 bpm were eligible for 10 mg. Propranolol was withheld in patients with lower baseline HR or clinical/hemodynamic features favoring avoidance of beta-blockade. The primary outcome was achieving HR <65 bpm at the time of CCTA. Secondary outcomes included HR reduction and adverse events.</div></div><div><h3>Results</h3><div>Of 113 patients, 73 received propranolol and 40 were withheld propranolol. At admission, patients receiving propranolol had higher HR, whereas those not receiving propranolol more frequently had atrial fibrillation, coronary artery disease, and previous beta blocker use. Propranolol group showed significant HR reduction from 76.3±11 bpm to a median HR of 66 bpm (p<0.001). No HR reduction was noted in the non-propranolol group. At CCTA, 43.4% of propranolol patients met the target HR <em>vs.</em> 43.3% of the non-propranolol group. No major adverse events were observed.</div></div><div><h3>Conclusion</h3><div>In selected patients with severe AS undergoing pre-TAVI CCTA, oral propranolol was associated with significant within-group HR reduction and no major adverse events. However, target HR achievement was similar between groups, and this comparison is limited by non-randomized treatment allocation and baseline differences. These findings support the feasibility and preliminary safety of propranolol, while further studies are needed to establish its efficacy and impact on image quality.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 11","pages":"Pages 611-619"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical readiness and methodological rigor of artificial intelligence models for ventricular arrhythmia and sudden cardiac death prediction: A systematic review with PROBAST+AI appraisal","authors":"Mislav Puljevic, Marina Petrovic, Hana Ivandic, Nora Knez, Ana-Marija Brekalo, Lucija Kantolic, Branimir Pervan","doi":"10.1016/j.repc.2026.05.007","DOIUrl":"10.1016/j.repc.2026.05.007","url":null,"abstract":"<div><div>Sudden cardiac death (SCD) remains a major cause of mortality, and risk stratification based on left ventricular ejection fraction (LVEF) has significant limitations. Artificial intelligence (AI) has emerged as a potential approach for modeling complex arrhythmic risk. We conducted a systematic review with prespecified anchor subgroup reporting (without pooling) to evaluate the performance of AI models in predicting SCD and malignant ventricular arrhythmias. We searched MEDLINE/PubMed, Embase, and Scopus from inception to 3 October 2025. Anchor subgroup reporting was restricted to studies reporting area under the receiver-operating characteristic curve (AUROC) with 95% confidence intervals (CIs) within predefined modality/horizon subgroups. Studies without CIs or relying on cross-validation variance were summarized narratively as supplementary evidence. Thirteen studies met the inclusion criteria; five reported AUROC with 95% CIs within prespecified modality/horizon subgroups and were included as anchor subgroup estimates (k=1 per subgroup). Methodological quality and reporting were limited: 54% of studies (7/13) were classified as high risk of bias according to PROBAST+AI, driven by cross-validation-only designs, unit-of-analysis issues, limited external validation, and sparse calibration reporting. Among anchor estimates, deep learning on single-lead ambulatory ECG showed high discrimination for near-term ventricular tachyarrhythmias (AUROC 0.948, 95% CI 0.926–0.967), while 12-lead ECG models achieved good performance for long-term SCD (AUROC 0.820, 95% CI 0.794–0.847). The multimodal anchor estimate (AUROC 0.84) was numerically higher than the CMR radiomics anchor (AUROC 0.70), but this represents an indirect between-study contrast. AI-ECG models show high reported discrimination in near-term risk windows, but cross-study comparisons are indirect, and methodological heterogeneity remains a barrier to translation into clinical practice.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 11","pages":"Pages 649-660"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carlos Domínguez-Massa, Eduardo Tébar-Botí, Juan Bautista Martínez-León
{"title":"Response to “Comment on predictive factors of mortality with short-term ventricular assist devices for heart transplantation”","authors":"Carlos Domínguez-Massa, Eduardo Tébar-Botí, Juan Bautista Martínez-León","doi":"10.1016/j.repc.2026.08.007","DOIUrl":"10.1016/j.repc.2026.08.007","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 11","pages":"Pages 665-666"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149041537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}